These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35710373)

  • 1. Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.
    Donkoh ET; Dassah ET; Owusu-Dabo E
    BMC Womens Health; 2022 Jun; 22(1):234. PubMed ID: 35710373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men.
    Chow EPF; Fairley CK; Zou H; Wigan R; Garland SM; Cornall AM; Atchison S; Tabrizi SN; Chen MY
    Clin Infect Dis; 2022 Aug; 75(2):323-329. PubMed ID: 34971362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
    Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.
    Bhatla N; Muwonge R; Malvi SG; Joshi S; Poli URR; Lucas E; Esmy PO; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Vashist S; Mishra G; Jadhav R; Siddiqi M; Anantharaman D; Panicker G; Butt J; Sankaran S; Kannan TPRA; Varghese R; Kartha P; Pillai MR; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P
    Hum Vaccin Immunother; 2023 Dec; 19(3):2289242. PubMed ID: 38078840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
    Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
    Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.
    Joshi S; Anantharaman D; Muwonge R; Bhatla N; Panicker G; Butt J; Rani Reddy Poli U; Malvi SG; Esmy PO; Lucas E; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Pillai Rameshwari Ammal Kannan T; Kartha P; Shastri SS; Sauvaget C; Radhakrishna Pillai M; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P
    Vaccine; 2023 Jan; 41(1):236-245. PubMed ID: 36446654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls.
    Laake I; Feiring B; Jonassen CM; Pettersson JHO; Frengen TG; Kirkeleite IØ; Trogstad L
    J Infect Dis; 2022 Sep; 226(4):625-633. PubMed ID: 33205203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
    Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
    Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls.
    Pasmans H; Schurink-Van't Klooster TM; Bogaard MJM; van Rooijen DM; de Melker HE; Welters MJP; van der Burg SH; van der Klis FRM; Buisman AM
    Vaccine; 2019 Nov; 37(49):7280-7288. PubMed ID: 31575492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
    Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
    Lin L; Macias Parra M; Sierra VY; Salas Cespedes A; Granados MA; Luque A; Karkada N; Castrejon Alba MM; Romano-Mazzotti L; Borys D; Struyf F
    Pediatr Infect Dis J; 2019 Oct; 38(10):1061-1067. PubMed ID: 31469776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges.
    Parker KH; Kemp TJ; Pan Y; Yang Z; Giuliano AR; Pinto LA
    Vaccine; 2018 May; 36(19):2705-2711. PubMed ID: 29631883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.
    Kann H; Lehtinen M; Eriksson T; Surcel HM; Dillner J; Faust H
    J Infect Dis; 2021 Jun; 223(11):1992-2000. PubMed ID: 33009576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.